Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Eli Lilly (NYSE:LLY) has partnered with the British ... tirzepatide, branded as Zepbound. Writing for the U.K.’s The Telegraph newspaper, Secretary of State for Health & Social Care Wes ...